Unresolved questions regarding the promise of the TPEx regimen

Makoto Kosaka¹, Yoshitaka Honma², Hiroto Ishiki³

Affiliations

¹ Faculty of Medicine, The University of Tokyo, Tokyo, Japan.
² Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan.
³ Department of Palliative Medicine, National Cancer Center Hospital, Tokyo 104-0045, Japan. Electronic address: ishiki-tky@umin.ac.jp.

PMID: 34087137
DOI: 10.1016/S1470-2045(21)00246-1

Comment

Unresolved questions regarding the promise of the TPEx regimen

Makoto Kosaka et al. Lancet Oncol. 2021 Jun.

. 2021 Jun;22(6):e227.

doi: 10.1016/S1470-2045(21)00246-1.

Authors

Makoto Kosaka¹, Yoshitaka Honma², Hiroto Ishiki³

Affiliations

¹ Faculty of Medicine, The University of Tokyo, Tokyo, Japan.
² Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan.
³ Department of Palliative Medicine, National Cancer Center Hospital, Tokyo 104-0045, Japan. Electronic address: ishiki-tky@umin.ac.jp.

PMID: 34087137
DOI: 10.1016/S1470-2045(21)00246-1

No abstract available

PubMed Disclaimer

Conflict of interest statement

YH declares institutional contract research expenses and lecture fees from Merck Biopharma and Chugai Pharma. MK and HI declare no competing interests.

Comment in

Unresolved questions regarding the promise of the TPEx regimen - Authors' reply.
Guigay J, Auperin A, Fraslin A, Keilholz U, Bourhis J, Mesia R. Guigay J, et al. Lancet Oncol. 2021 Jun;22(6):e228-e229. doi: 10.1016/S1470-2045(21)00293-X. Lancet Oncol. 2021. PMID: 34087138 No abstract available.

Comment on

Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial.
Guigay J, Aupérin A, Fayette J, Saada-Bouzid E, Lafond C, Taberna M, Geoffrois L, Martin L, Capitain O, Cupissol D, Castanie H, Vansteene D, Schafhausen P, Johnson A, Even C, Sire C, Duplomb S, Evrard C, Delord JP, Laguerre B, Zanetta S, Chevassus-Clément C, Fraslin A, Louat F, Sinigaglia L, Keilholz U, Bourhis J, Mesia R; GORTEC; AIO; TTCC, and UniCancer Head and Neck groups. Guigay J, et al. Lancet Oncol. 2021 Apr;22(4):463-475. doi: 10.1016/S1470-2045(20)30755-5. Epub 2021 Mar 5. Lancet Oncol. 2021. PMID: 33684370 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Unresolved questions regarding the promise of the TPEx regimen

Affiliations

Unresolved questions regarding the promise of the TPEx regimen

Authors

Affiliations

Conflict of interest statement

Comment in

Comment on

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources